help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, S. R.
Right arrow Articles by Tsai, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, S. R.
Right arrow Articles by Tsai, J. H.

Journal of Clinical Endocrinology & Metabolism, Vol 78, 483-491, Copyright © 1994 by Endocrine Society


ARTICLES

Mutations of the p53 gene in human functional adrenal neoplasms

SR Lin, YJ Lee and JH Tsai
Department of Internal Medicine and Clinical Pathology, Kaohsiung Medical College, Taiwan, Republic of China.

To clarify gene alterations in functional human adrenal tumors, we performed molecular analysis for p53 abnormalities in 23 cases with adrenal neoplasms. The immunohistochemical study with anti-p53 monoclonal antibody pAb1801 demonstrated that 10 of 23 (43.5%) cases overexpressed p53 protein in the tumor cells. Using a polymerase chain reaction-single strand conformation polymorphism study, 5 of 6 (83.3%) pheochromocytoma tissues (1 malignant and 5 benign) and 11 of 15 (73.3%) adrenocortical adenomas (2 with Cushing's syndrome and 13 with primary aldosteronism, all benign) showed an apparent electrophoretic mobility shift between the tumor and its paired adjacent normal adrenal tissue. Such differences were detected in exon 4 (12 cases), exon 5 (2 cases), and exon 7 (3 cases). The types of these mutations in exon 4 were a substitution from threonine (ACC) to isoleucine (ATC) at codon 102 in 5 cases, from glutamine (CAG) to histidine (CAC) at codon 104 in 1 case, from glycine (GGG) to alanine (CGG) at codon 117 in 1 case, from glutamate (GAG) to glutamine (CAG) at codon 68 in 1 case, and single base changes resulting in a premature stop codon at codon 100 in 2 cases. A 2-basepair deletion at codon 175 in exon 5 resulting in a frame shift was identified in 1 case. A single point mutation was identified, resulting in the substitution of glutamine (CAG) for arginine (CGG) at codon 248 of exon 7 in 1 case. A single basepair deletion at codon 249 resulted in a frame shift in 2 cases. There was 1 case with malignant pheochromocytoma that combined a single point mutation in exon 4 and a single base deletion in exon 7. Only 2 of 23 cases showed a loss of a normal allele encoding in the p53 gene. Northern blot analysis with 1.8-kilobase p53 cDNA revealed that p53 mRNA was overexpressed in 6 cases. Our results indicate that high frequencies of p53 gene mutation, especially in exon 4, exist in functional adrenal tumors. As p53 protein is a regulator of guanine nucleotide synthesis, the loss of normal inhibitory regulation by the p53 mutation would serve to increase the availability of GTP for the transduction of signals essential for increased cell growth and hormone expression in the adrenal tumors. These findings suggest that the p53 gene mutation may play a role in the tumorigenesis of benign and functional human adrenal tumors.


This article has been cited by other articles:


Home page
The OncologistHome page
P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu
Molecular Markers and the Pathogenesis of Adrenocortical Cancer
Oncologist, May 1, 2008; 13(5): 548 - 561.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. Libe, A. Fratticci, and J. Bertherat
Adrenocortical cancer: pathophysiology and clinical management
Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Libe, L. Groussin, F. Tissier, C. Elie, F. Rene-Corail, A. Fratticci, E. Jullian, P. Beck-Peccoz, X. Bertagna, C. Gicquel, et al.
Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity
Clin. Cancer Res., February 1, 2007; 13(3): 844 - 850.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Tanahashi, T. Mune, Y. Takahashi, M. Isaji, T. Suwa, H. Morita, N. Yamakita, K. Yasuda, T. Deguchi, P. C. White, et al.
Association of Lys173Arg Polymorphism with CYP11B2 Expression in Normal Adrenal Glands and Aldosterone-Producing Adenomas
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6226 - 6231.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Libe and J. Bertherat
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
D E Schteingart, G M Doherty, P G Gauger, T J Giordano, G D Hammer, M Korobkin, and F P Worden
Management of patients with adrenal cancer: recommendations of an international consensus conference
Endocr. Relat. Cancer, September 1, 2005; 12(3): 667 - 680.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. P. Cregan, N. A. Arbour, J. G. MacLaurin, S. M. Callaghan, A. Fortin, E. C. C. Cheung, D. S. Guberman, D. S. Park, and R. S. Slack
p53 Activation Domain 1 Is Essential for PUMA Upregulation and p53-Mediated Neuronal Cell Death
J. Neurosci., November 3, 2004; 24(44): 10003 - 10012.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez
Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. J. Giordano, D. G. Thomas, R. Kuick, M. Lizyness, D. E. Misek, A. L. Smith, D. Sanders, R. T. Aljundi, P. G. Gauger, N. W. Thompson, et al.
Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis
Am. J. Pathol., February 1, 2003; 162(2): 521 - 531.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Koch, K. Pacak, and G. P. Chrousos
The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Sarkar, T. Imai, F. Kambe, A. Shibata, S. Ohmori, A. Siddiq, S. Hayasaka, H. Funahashi, and H. Seo
The Human Homolog of Diminuto/Dwarf1 Gene (hDiminuto): A Novel ACTH-Responsive Gene Overexpressed in Benign Cortisol-Producing Adrenocortical Adenomas
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5130 - 5137.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico, E. M. Pinto, S. Domenice, M. C. B. V. Fragoso, R. M. Martin, M. C. Zerbini, A. M. Lucon, and B. B. Mendonca
An Inherited Mutation Outside the Highly Conserved DNA-Binding Domain of the p53 Tumor Suppressor Protein in Children and Adults with Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4970 - 4973.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Gicquel, X. Bertagna, V. Gaston, J. Coste, A. Louvel, E. Baudin, J. Bertherat, Y. Chapuis, J.-M. Duclos, M. Schlumberger, et al.
Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors
Cancer Res., September 1, 2001; 61(18): 6762 - 6767.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
K Y Lam, C Y Lo, N M S Wat, J M Luk, and K S L Lam
The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas
J. Clin. Pathol., June 1, 2001; 54(6): 443 - 448.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Sarkar, T. Imai, F. Kambe, A. Shibata, S. Ohmori, S. Hayasaka, H. Funahashi, and H. Seo
Overexpression of Glutathione-S-Transferase A1 in Benign Adrenocortical Adenomas from Patients with Cushing's Syndrome
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1653 - 1659.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
F. de Fraipont, M. El Atifi, C. Gicquel, X. Bertagna, E. M. Chambaz, and J. J. Feige
Expression of the Angiogenesis Markers Vascular Endothelial Growth Factor-A, Thrombospondin-1, and Platelet-Derived Endothelial Cell Growth Factor in Human Sporadic Adrenocortical Tumors: Correlation with Genotypic Alterations
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4734 - 4741.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Wilkin, N. Gagné, J. Paquette, L. L. Oligny, and C. Deal
Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2048 - 2056.
[Abstract] [Full Text]


Home page
HypertensionHome page
P. Mulatero, D. Schiavone, F. Fallo, F. Rabbia, C. Pilon, L. Chiandussi, L. Pascoe, and F. Veglio
CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism
Hypertension, March 1, 2000; 35(3): 694 - 698.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Pilon, M. Pistorello, A. Moscon, G. Altavilla, U. Pagotto, M. Boscaro, and F. Fallo
Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2776 - 2779.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. R. Bornstein, C. A. Stratakis, and G. P. Chrousos
Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management
Ann Intern Med, May 4, 1999; 130(9): 759 - 771.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. C. Figueiredo, C. A. Stratakis, R. Sandrini, L. DeLacerda, M. A. D. Pianovsky, C. Giatzakis, H. M. Young, and B. R. Haddad
Comparative Genomic Hybridization Analysis of Adrenocortical Tumors of Childhood
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 1116 - 1121.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Reincke, P. Mora, F. Beuschlein, W. Arlt, G. P. Chrousos, and B. Allolio
Deletion of the Adrenocorticotropin Receptor Gene in Human Adrenocortical Tumors: Implications for Tumorigenesis
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3054 - 3058.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Gicquel, M.-L. Raffin-Sanson, V. Gaston, X. Bertagna, P.-F. Plouin, M. Schlumberger, A. Louvel, J.-P. Luton, and Y. Le Bouc
Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2559 - 2565.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico and G. P. Chrousos
Adrenocortical Tumors
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1317 - 1324.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society